2001 Junipero Serra Blvd. Suite 400
About DNA Script
DNA Script is a leading company in manufacturing de novo synthetic nucleic acids using enzymatic DNA synthesis (EDS) technology. The company aims at accelerating innovation in life science and technology through the decentralization of rapid, on demand and high-quality DNA synthesis. DNA Script's approach leverages nature's billions of years of evolution in synthesizing DNA to set a new standard for customizing nucleic acid synthesis thus accelerating discovery in genetics, genomics, and synthetic biology. Discovery disciplines with profound impacts upon humanity such as biopharma, translational genetics and even molecular information storage all start with synthetic DNA. The company has recently initiated the commercialization of its first EDS powered platform, the SYNTAX system.
To date, DNA Script has raised over $315M of financing, with leading investors such as Coatue Management, Fidelity Management and Research, Catalio Capital Management, Casdin Capital, LSP, Bpifrance Large Ventures, Danaher, Illumina Ventures, Agilent, Merck Ventures, Sofinnova Partners, Kurma Partners, T Rowe Price, Baillie Gifford and Eurazeo.
DNA Script also partners on technology and product development with leading organizations such as DARPA, IARPA, Moderna Therapeutics, GE Research, Illumina, the Broad Institute, Harvard University, Institut Pasteur and the French Department of Defense.
DNA Script has its research and manufacturing facilities headquartered in Paris, France, and is in the process of expanding its commercial and development teams in South San Francisco.
Opportunity and Challenges
We are looking to assemble a team of best-in-class, innovative and passionately eager people. We want to gather their talents and skills to achieve one goal: unlock the power of “DNA-write.” We offer the opportunity of joining a dynamic, international, and highly skilled team in a pioneering startup. Our DNA On Demand platform not only has the potential to change the way the world makes and uses synthetic DNA, but also to accelerate the rate of discovery by delivering upon the promise of same-day results.
This is an opportunity to join a rapidly growing company and to have a large impact on developing a technology that will have far-reaching impacts across biological sciences.
French office: 67 avenue de Fontainebleau, 94 270 Le Kremlin-Bicêtre
US Headquarters: 2001 Junipero Serra Blvd. Suite 400, Daly City, CA 94014, USA
Discover DNA Script with Eliot, Talent Acquisition Lead
33 articles about DNA Script
DNA Script to Unveil Industry’s Most Versatile On-site, On-Demand DNA Printer at the World’s Largest Synthetic Biology Conference
DNA Script announced the broad commercial availability of the fully automated SYNTAX™ DNA printing platform, which consists of the benchtop STX-200 system, latest biochemistry advancements, robust reagent kits, and intuitive software enhancements.
DNA Script Extends Distributorships to Middle East to Expand Access to Same-day Enzymatic DNA Synthesis
DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, has signed distribution agreements in the Middle East with Gulf Scientific Corporation and Eisenberg Ltd. to expand its worldwide footprint of sales, service and support.
DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, won the Grand Prize Trophy at the 2022 Future Unicorns Awards, whose ceremony took place on September 15, 2022, at the Bourrienne Hotel.
French Defense Innovation Agency Investigates the Use of DNA Script’s SYNTAX System to Synthesize Custom qPCR Probes for On-demand Detection of Biothreats
DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, has announced the first successful qPCR assays using primers and probes synthesized by a customer via enzymatic synthesis using the company’s SYNTAX System DNA printer.
Life sciences and biopharma companies strengthen their leadership teams and boards with these Movers & Shakers.
DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, has added life sciences veteran Chris Barbazette as Chief Commercial Officer to its leadership team.
DNA Script Launches Early Access Program for Latest Advancements to the SYNTAX Platform and Enzymatic DNA Synthesis Technology
DNA Script, a world leader in Enzymatic DNA Synthesis for DNA on demand, announced the launch of a new program for customers of their SYNTAX System, in which organizations receive early access to the latest advancements of their EDS technology.
DNA Script Partners with Asia-Pacific Distributors as Part of Global Expansion to Meet Demand for Same-day Enzymatic DNA Synthesis
DNA Script has reached agreements with several leading biotechnology distribution companies throughout the Asia-Pacific region, including Cold Spring Biotech Corp., Research Instruments Pte. Ltd., Premas Life Sciences Pvt. Ltd. and Bio-Medical Science Co. Ltd.
DNA Script, a world leader in Enzymatic DNA Synthesis (EDS) and DNA on demand, has been named to Fast Company ’s prestigious annual list of the World’s Most Innovative Companies for 2022.
DNA Script, a leader in Enzymatic DNA Synthesis and DNA on demand, has inked a multi-million dollar, multi-year contract with Wellcome Leap to accelerate RNA products, including mRNA vaccines, and advance RNA therapies.
Company to Present Monday, January 10, 2022, at 2 p.m. EST.
Here's who rang in the New Year by joining the NASDAQ or raising private equity funds.
DNA Script, a pioneer in Enzymatic DNA Synthesis for on-demand DNA printing, announced the completion of its Series C financing, raising $200 million of new capital.
DNA Script announced it secured a $200 million Series C financing, bringing the total amount raised by the biotech company to $315 million since its founding in 2014.
DNA Script, a leader in Enzymatic DNA Synthesis, announced the CE marking of its SYNTAX System, the first EDS-powered benchtop DNA printer.
DNA Script, a leader in Enzymatic DNA Synthesis, announced that Blanche Savary de Beauregard has joined the company as General Counsel.
DNA Script to Develop Next Generation of Enzymatic DNA Synthesis Printers with $2.2 Million Grant Award from the National Human Genome Research Institute of the NIH
DNA Script, a leader in benchtop enzymatic DNA synthesis, announced that the company has received a $2.2 million grant award from the National Human Genome Research Institute of the National Institutes of Health to support the ongoing development of next generation printers to enzymatically print synthetic DNA and RNA as a follow-on to their recently launched SYNTAX System.
10/27/2021While the volatility of the market has some shying away from going public, private investment dollars are still rolling in each week. Check out our top picks.
DNA Script Raises $165M in Oversubscribed Series C Financing to Accelerate Commercialization of Enzymatic DNA Printing Platform
DNA Script, a pioneer in Enzymatic DNA Synthesis and DNA printing on demand, announced it has raised $165 million in a Series C financing led by Coatue Management and Catalio Capital Management, whose representatives have joined as Board observers.
DNA Script Appoints Don Kania as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as Independent Director
DNA Script, a leader in Enzymatic DNA Synthesis, announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.